Center for
Congenital & Structural Heart Disease, Section Chief of Pediatric
Cardiology, and Professor of Pediatrics & Internal Medicine at Rush
University Medical Center (Chicago, IL).
"The take-away message is that SYNTAX has extended the spectrum of care
for a large number of patients with very complex coronary artery disease.
For some, bypass surgery will still be the most appropriate option, but
many more patients now have another choice," says Dr. Feldman.
About SCAI
Headquartered in Washington, D.C., The Society for Cardiovascular
Angiography and Interventions is a 4,000-member professional organization
representing invasive and interventional cardiologists in more than 60
countries. SCAI's mission is to promote excellence in invasive and
interventional cardiovascular medicine through physician education and
representation, and advancement of quality standards to enhance patient
care. SCAI's annual meeting has become the leading venue for education,
discussion, and debate about the latest developments in this dynamic
medical specialty. SCAI's new patient and physician education program,
Seconds Count, offers comprehensive information about cardiovascular
disease. For more information about SCAI and Seconds Count, visit
http://www.scai.org or http://www.seconds-count.org.
'/>"/>SOURCE Society for Cardiovascular Angiography and Interventions(SCAI) Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI2.
New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option3.
ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer4.
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma5.
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 34546.
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics7.
Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes8.
GSK Does Not Option XL784 for Further Development9.
American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation10.
Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel11.
CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System